AERs for OTCs
This article was originally published in The Tan Sheet
Executive Summary
FDA is "trying to propose a rule for OTC products with FDA reporting requirements," Office of Drug Safety Division of Drug Risk Evaluation Associate Director Min Chen said at a DIA Pharmacovigilance meeting in Washington, D.C. Jan. 24. The goal is to plug the "big hole in the safety reporting game" caused by monograph OTC drugs, Chen explained. Initial development of funding is coming from some of last year's funds, she said. "Congress is behind us as far as OTC products and dietary supplements, and hopefully, this will be next year, we'll have some updates in this area"...
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.